Brief: Roivant And Priovant Announce Positive Phase 3 Valor Study Results For Brepocitinib In 52-Week Placebo-Controlled Trial In Dermatomyositis (Dm)
17/09/2025 14:16
Sept 17 (Reuters) - Roivant Sciences Ltd ROIV.O: ROIVANT AND PRIOVANT ANNOUNCE POSITIVE PHASE 3 VALOR STUDY RESULTS FOR BREPOCITINIB IN 52-WEEK PLACEBO-CONTROLLED TRIAL IN DERMATOMYOSITIS (DM) ROIVANT SCIENCES LTD - NDA FILING FOR BREPOCITINIB PLANNED FOR 1H 2026 Source text: ID:nGNX4sJ1LZ Further company coverage: ROIV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple